Safety and efficacy of oral semaglutide versus dulaglutide in Japanese patients with type 2 diabetes (PIONEER 10): an open-label, randomised, active-controlled, phase 3a trial

著者: Daisuke Yabe, Jiro Nakamura, Hideaki Kaneto, Srikanth Deenadayalan, Andrea Navarria, Mette Gislum, Nobuya Inagaki, T Arisaka, Toshihisa Asakura, Naoto Azuma, Sumiaki Fukuda, Yasushi Fukushima, Norio Harada, Shin‐ichiro Inoue, Hitoshi Ishida, Hiroshi Ishii, San‐e Ishikawa, Hideaki Jinnouchi, Shizuka Kaneko, K. Kanno, Mai Kato, Yoichiro Kato, Tatsushi Kawada, Hyun-Mi Kim, Arihiro Kiyosue, Osamu Matsuoka, Otoya Miho, S. Nakamoto, Susumu Nakamura, Shuhei Nakanishi, Hideki Nishimura, Akira Numata, T. Ohama, Tomoko Okabe, FUMINOBU OKUGUCHI, Takeshi Osonoi, T Sasaki, Hiroaki Seino, Koki Shin, Toshihiko Shiraiwa, Toshiyuki Sugiura, Seiki Wada, Akira Yamauchi - The Lancet 2020 被引用: 203